Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Monopar Therapeutics Inc (MNPR) USD0.001

Sell:$4.92 Buy:$4.97 Change: $0.14 (2.77%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.14 (2.77%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.14 (2.77%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Monopar Therapeutics Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapeutics for cancer patients. Its pipeline includes Validive, Camsirubicin and MNPR-101. Validive is a clonidine mucobuccal tablet (clonidine MBT). Validive is designed to be used prophylactically to reduce the incidence, delay the time to onset, and decrease the duration of severe oral mucositis in patients undergoing chemoradiotherapy for oropharyngeal cancer. Its second product candidate, Camsirubicin, is a novel analog of doxorubicin. Camsirubicin is designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining anti-cancer activity. MNPR-101 is a humanized monoclonal antibody designed to bind a specific cell surface receptor found on cancer cells, the urokinase plasminogen activator receptor (uPAR), and to interrupt several pathways required for tumor growth and progression. It is developing MNPR-101 for the treatment of advanced cancers.

Contact details

1000 Skokie Blvd Ste 350
United States
+1 (847) 3880349

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$66.31 million
Shares in issue:
12.58 million
United States
US dollar

Key personnel

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.